These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 31841311)
1. Protein Footprinting and X-ray Crystallography Reveal the Interaction of PD-L1 and a Macrocyclic Peptide. Niu B; Appleby TC; Wang R; Morar M; Voight J; Villaseñor AG; Clancy S; Wise S; Belzile JP; Papalia G; Wong M; Brendza KM; Lad L; Gross ML Biochemistry; 2020 Feb; 59(4):541-551. PubMed ID: 31841311 [TBL] [Abstract][Full Text] [Related]
2. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005 [TBL] [Abstract][Full Text] [Related]
3. Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis. Zyla E; Musielak B; Holak TA; Dubin G Molecules; 2021 Aug; 26(16):. PubMed ID: 34443436 [TBL] [Abstract][Full Text] [Related]
4. Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective. Shi D; Zhou S; Liu X; Zhao C; Liu H; Yao X Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):576-588. PubMed ID: 29203283 [TBL] [Abstract][Full Text] [Related]
5. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. Guzik K; Zak KM; Grudnik P; Magiera K; Musielak B; Törner R; Skalniak L; Dömling A; Dubin G; Holak TA J Med Chem; 2017 Jul; 60(13):5857-5867. PubMed ID: 28613862 [TBL] [Abstract][Full Text] [Related]
6. Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method. Lim H; Chun J; Jin X; Kim J; Yoon J; No KT Sci Rep; 2019 Nov; 9(1):16727. PubMed ID: 31723178 [TBL] [Abstract][Full Text] [Related]
7. Fragment-based screening of programmed death ligand 1 (PD-L1). Perry E; Mills JJ; Zhao B; Wang F; Sun Q; Christov PP; Tarr JC; Rietz TA; Olejniczak ET; Lee T; Fesik S Bioorg Med Chem Lett; 2019 Mar; 29(6):786-790. PubMed ID: 30728114 [TBL] [Abstract][Full Text] [Related]
8. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy. Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417 [TBL] [Abstract][Full Text] [Related]
9. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature. Kopalli SR; Kang TB; Lee KH; Koppula S Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857 [TBL] [Abstract][Full Text] [Related]
10. Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint. Magiera-Mularz K; Skalniak L; Zak KM; Musielak B; Rudzinska-Szostak E; Berlicki Ł; Kocik J; Grudnik P; Sala D; Zarganes-Tzitzikas T; Shaabani S; Dömling A; Dubin G; Holak TA Angew Chem Int Ed Engl; 2017 Oct; 56(44):13732-13735. PubMed ID: 28881104 [TBL] [Abstract][Full Text] [Related]
11. Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation. Pan C; Yang H; Lu Y; Hu S; Wu Y; He Q; Dong X Eur J Med Chem; 2021 Mar; 213():113170. PubMed ID: 33454550 [TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules. Geng Q; Jiao P; Jin P; Su G; Dong J; Yan B Curr Pharm Des; 2018 Feb; 23(39):6033-6041. PubMed ID: 28982322 [TBL] [Abstract][Full Text] [Related]
13. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy. Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814 [TBL] [Abstract][Full Text] [Related]
14. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules. Yang J; Hu L Med Res Rev; 2019 Jan; 39(1):265-301. PubMed ID: 30215856 [TBL] [Abstract][Full Text] [Related]
15. Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective. Wu X; Meng Y; Liu L; Gong G; Zhang H; Hou Y; Liu C; Wu D; Qin M Bioorg Med Chem; 2021 Mar; 33():116038. PubMed ID: 33517226 [TBL] [Abstract][Full Text] [Related]
16. Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy. Chen R; Yuan D; Ma J Future Med Chem; 2022 Jan; 14(2):97-113. PubMed ID: 34870447 [TBL] [Abstract][Full Text] [Related]
17. Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization. Guo Y; Jin Y; Wang B; Liu B Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946261 [TBL] [Abstract][Full Text] [Related]
18. Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction. Kawashita S; Aoyagi K; Yamanaka H; Hantani R; Naruoka S; Tanimoto A; Hori Y; Toyonaga Y; Fukushima K; Miyazaki S; Hantani Y Bioorg Med Chem Lett; 2019 Sep; 29(17):2464-2467. PubMed ID: 31351692 [TBL] [Abstract][Full Text] [Related]
19. Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules. Lin X; Lu X; Luo G; Xiang H Eur J Med Chem; 2020 Jan; 186():111876. PubMed ID: 31761384 [TBL] [Abstract][Full Text] [Related]
20. The Stone Guest: How Does pH Affect Binding Properties of PD-1/PD-L1 Inhibitors? Riccio A; Coletti A; Dolciami D; Mammoli A; Cerra B; Moretti S; Gioiello A; Ferlin S; Puxeddu E; Macchiarulo A ChemMedChem; 2021 Feb; 16(3):568-577. PubMed ID: 33085193 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]